Charlotte M. N

Jun 13, 2024 | pubs.acs.org | Lennart Brewitz |Christopher J Schofield |R. E. Scott |Charlotte M. N

FiguresReferencesSupport InfoFigure 1 This article references 56 other publications. 1Owen, D. R.; Allerton, C. M. N.; Anderson, A. S.; Aschenbrenner, L.; Avery, M.; Berritt, S.; Boras, B.; Cardin, R. D.; Carlo, A.; Coffman, K. J. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.